NovaBay Pharmaceuticals Inc Total Assets
NovaBay Pharmaceuticals Inc total assets. Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) holds total assets worth $9.04 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NovaBay Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of NovaBay Pharmaceuticals Inc (2003–2025)
Total assets of NovaBay Pharmaceuticals Inc from 2003 to 2025. This chart illustrates how NovaBay Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See NovaBay Pharmaceuticals Inc share price for real-time trading data and today's change.
NovaBay Pharmaceuticals Inc - Asset Composition Analysis
NovaBay Pharmaceuticals Inc Total Assets Breakdown (December 2025)
NovaBay Pharmaceuticals Inc total assets breakdown as of December 2025. NovaBay Pharmaceuticals Inc's total assets of $9.04 Million consist of 96.0% current assets and 4.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is NovaBay Pharmaceuticals Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NovaBay Pharmaceuticals Inc's current assets represent 96.0% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 88.1% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
NovaBay Pharmaceuticals Inc Competitors by Total Assets
Key competitors of NovaBay Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
NovaBay Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.60 | 0.68 | 4.27 |
| Quick Ratio | 7.60 | 0.41 | 3.99 |
| Cash Ratio | 0.00 | 0.15 | 0.00 |
| Working Capital | $7.53 Million | $-908.00K | $10.07 Million |
NovaBay Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between NovaBay Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.53 |
| Latest Market Cap to Assets Ratio | 3.57 |
| Asset Growth Rate (YoY) | 163.9% |
| Total Assets | $9.04 Million |
| Market Capitalization | $32.22 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NovaBay Pharmaceuticals Inc's assets at a significant premium (3.57x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: NovaBay Pharmaceuticals Inc's assets grew by 163.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NovaBay Pharmaceuticals Inc (2003–2025)
The table below shows the annual total assets of NovaBay Pharmaceuticals Inc from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.04 Million | +163.95% |
| 2024-12-31 | $3.42 Million | -62.11% |
| 2023-12-31 | $9.03 Million | -44.91% |
| 2022-12-31 | $16.40 Million | -31.61% |
| 2021-12-31 | $23.98 Million | +57.36% |
| 2020-12-31 | $15.24 Million | +35.81% |
| 2019-12-31 | $11.22 Million | +19.86% |
| 2018-12-31 | $9.36 Million | -7.12% |
| 2017-12-31 | $10.08 Million | -34.47% |
| 2016-12-31 | $15.38 Million | +202.95% |
| 2015-12-31 | $5.08 Million | -32.64% |
| 2014-12-31 | $7.54 Million | -51.84% |
| 2013-12-31 | $15.65 Million | -18.64% |
| 2012-12-31 | $19.23 Million | +20.50% |
| 2011-12-31 | $15.96 Million | +2.88% |
| 2010-12-31 | $15.52 Million | -11.45% |
| 2009-12-31 | $17.52 Million | +25.44% |
| 2008-12-31 | $13.97 Million | -41.61% |
| 2007-12-31 | $23.92 Million | +101.60% |
| 2006-12-31 | $11.87 Million | +233.13% |
| 2005-12-31 | $3.56 Million | +170.87% |
| 2003-12-31 | $1.31 Million | -- |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more